Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
An orally delivered GLP-1 analog coformulated with the absorption enhancer SNAC achieves transcellular-directed absorption in the stomach.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Yet, its adoption is restricted by a complicated dosing protocol that necessitates administration while fasting with water, as well as the avoidance of food or medications for a minimum of 30 min afterward. Such requirements reduce convenience and compromise adherence in routine practice [11, 16].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [16]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Pharmacologically, long-acting GLP-1 receptor agonists (GLP-1RAs) exhibit glucoregulatory functions via a triumvirate of mechanisms, namely, stimulation of insulin release in a glucose-dependent manner, suppression of glucagon activity during hyperglycemia, and a minor delay of gastric emptying resulting in slower glu…”
BackgroundDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1×
“In line with this, recent advancements in fatty acid acylation– based protraction technology have provided the possibility of achieving extended plasma half-lives (t1⁄2) without increasing molecular size, leading to the discovery of semaglutide, a GLP-1 analog with a t1⁄2 of ~1 week in humans (8).”
BackgroundSelf-citationThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“In addition, GLP-1 promotes satiety and reduces energy intake by virtue of its neurotransmitter role in brainstem-hypothalamus pathways signaling satiety (3, 4), and some long-acting GLP-1RAs including semaglutide have shown cardiovascular risk reduction (5, 6).”
BackgroundSelf-citationIncretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Self-citationpH stability and activity curves of pepsin with special reference to their clinical importance.
Piper, D. W., & Fenton, B. H. (1965) · Gut · doi:10.1136/gut.6.5.506 · Cited by 385
Intestinal permeation enhancers for oral peptide delivery
Maher, S., Mrsny, R. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.005 · Cited by 381
Cited by
Items 401–500 of 599
Pantanetti, P., Ronconi, V., Mancin, S., Carolis, C. D., Alberti, S., Pazzi, O., Marco, S. D., Michetti, G., Coacci, S., Mignini, V. E., et al. (2025) · Diabetology · doi:10.3390/diabetology6080080 · Cited by 3
The contributions of insulin to science in medicine
Kurtzhals, P., & Gough, S. C. L. (2021) · Diabetic Medicine · doi:10.1111/dme.14623 · Cited by 3
Шамхалова, М. Ш., & Shestakova, M. V. (2022) · Diabetes Mellitus · doi:10.14341/dm12941 · Cited by 3
Optimizing the Current Type 2 Diabetes Antidiabetics with Nanotechnologies: Where Do We Stand?
Abderrahmani, A., Szunerits, S., Dalle, S., & Boukherroub, R. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839165498-00092 · Cited by 3
Li, X., Sun, T., Du, X., Xie, X., & Shi, L. (2022) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2021-0533 · Cited by 3
Kesavadev, J., Ashik, A., Yasmin, S., Raj, K. S., Krishnan, G., Basanth, A., & Shankar, A. (2023) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_33_23 · Cited by 3
Engineering a Novel Mesoporous Silica-Lipid Hybrid Carrier for Oral Peptide Delivery
Tahan, M. A. A. (2023) · Aston Publications Explorer (Aston University) · doi:10.48780/publications.aston.ac.uk.00047172 · Cited by 3
Twarog, C. (2020) · theses.fr (ABES) · doi:10.70675/64939fcdzc6d7z4c62z9ea5zd405e5379fb7 · Cited by 3
Recent advances and perspectives in novel insulin release systems
Barkhordari, S., Samandari, S. S., Abdouss, M., & Pourmadadi, M. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106500 · Cited by 2
Tips and Tricks in Reversed-Phase Flash Chromatography for Peptide Purification
Denton, E. A., & Mehrotra, A. P. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4562-8_15 · Cited by 2
Cui, S., An, Y., Cui, Z., Liu, S., Li, H., Wen, X., Guan, J., Mao, S., Han, Y., & Zhang, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114504 · Cited by 2
Single-dose pharmacokinetics of sublingual semaglutide in rats
Liu, Y., Song, G., Banov, D., Denison, J., Davis, C., & Ip, K. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107406 · Cited by 2
Research advances in self-assembled peptide delivery systems for fibrosis treatment
Zhang, Y., Su, D., & Wang, Y. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100043 · Cited by 2
CREST-2: Early reflections on the primary results
Meschia, J. F., Lal, B. K., & Brott, T. (2026) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2026.02.002 · Cited by 2
Mageshkumar, H., Hesper, I. B., Dharani, D., Prabha, S. P., & Karthik, C. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02258-2 · Cited by 2
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
Oral delivery of biologics: from barrier-limited formulation to active convective transport
Niazi, S. K. (2026) · Frontiers in Drug Delivery · doi:10.3389/fddev.2026.1783113 · Cited by 2
Curto, R., Giglione, C., Cannarella, R., Berisha, H., Hattab, R., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Magni, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108278 · Cited by 2
Plotkin, M., Ivkovic, M., Smith, I., Rathor, N., Chowdhury, R., Hodkinson, A., & Kushner, R. F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70911 · Cited by 2
Breaking Permeation Barriers of Charged Molecules with Excess Permeation Enhancers
Bernaldez, M., Kang, C. H., Stamatis, S. D., Rose, J. P., & Sun, R. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6c02351 · Cited by 2
Semaglutide Bioavailability: Limitations, Formulation Innovation and Future Opportunities
Vahora, S., Shah, V., & Patel, B. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04185-2 · Cited by 2
Ehsasatvatan, M., & Kohnehrouz, B. B. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2329290 · Cited by 2
Arpaç, B., Pesce, C., Tognetti, F., Fragassi, A., Casagrande, L., Garofalo, M., Salmaso, S., & Caliceti, P. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125686 · Cited by 2
Insulin at 100: still central in protein-based therapy for chronic disease
Kurtzhals, P., von Scholten, B. J., Kreiner, F. F., & Gough, S. C. L. (2021) · Communications Medicine · doi:10.1038/s43856-021-00004-4 · Cited by 2
Clinical translation of oral peptide delivery technologies
Tyagi, P., & Subramony, J. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821061-1.00020-4 · Cited by 2
Design of potent and proteolytically stable double biaryl-stapled GLP-1R/GIPR peptide dual agonists
Yang, Y., & Lin, Q. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118215 · Cited by 2
Controlling Gastric Delivery of a GIP/GLP1 Peptide in Monkeys by Mucoadhesive SNAC Tablets
Tran, H., Martin, J. A., Dogra, M., Walker, J., Risley, D. S., & Aburub, A. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03881-9 · Cited by 2
Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis
Bandyopadhyay, I., Dave, S., Rai, A., Nampoothiri, M., Chamallamudi, M. R., & Kumar, N. (2021) · Current Drug Targets · doi:10.2174/1389450122666210901125420 · Cited by 2
Technological and Therapeutic Approaches to Type 2 Diabetes Management
Krishnan, R., Subramanian, R., & Selvarajan, R. (2023) · International Journal of Health Sciences and Research · doi:10.52403/ijhsr.20230320 · Cited by 2
Future Drug Treatments for Type 2 Diabetes
Bailey, C. J. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch79 · Cited by 2
Dahl, K., & Bækdal, T. A. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14485 · Cited by 2
Self-citationOral Semaglutide: A Novel Oral Preparation of GLP-1 Receptor Agonist
Mohan, B. P., & Eligar, V. S. (2021) · International Journal of Diabetes and Clinical Research · doi:10.23937/2377-3634/1410146 · Cited by 1
Rao, N., Jauhari, R., Sati, V., & Godiyal, P. (2022) · Journal of Applied Pharmaceutical Sciences and Research · doi:10.31069/japsr.v5i2.02 · Cited by 1
Hirotsu, T., Taniguchi, K., & Nishimura, R. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1520389 · Cited by 1
Mikami-Saito, Y., Maekawa, M., Watanabe, M., Hosaka, S., Takahashi, K., Totsune, E., Arai‐Ichinoi, N., Kikuchi, A., Kure, S., Katagiri, H., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072962 · Cited by 1
Rational design of site-specific artificial metallonucleases for therapeutic applications
Lu, X., & Zhang, C. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.113736 · Cited by 1
Drug discovery technologies–Current and future trends
Noe, M. C., Steppan, C. M., & Weston, A. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00019-4 · Cited by 1
Compatibility between Proteins and Polysaccharide Excipients in Oral Delivery Tablets
Jin, M.-J., Jing, Z.-Y., Liu, L.-D., Zheng, A., Wang, H., & Fang, W. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01413 · Cited by 1
Zhao, W., Yin, Y., Shi, Z., Yang, K., Li, X., Yang, Y., Jing, T., & Kang, Z. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11213-7 · Cited by 1
Dietrich, S., Karagianni, S., Ceulemans, J., Hermans, E., Bevernage, J., Reppas, C. I., & Vertzoni, M. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107185 · Cited by 1
Kaufmann, D., & Schlesinger, N. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070865 · Cited by 1
Han, C.-S., Choi, Y. R., Jung, W.-Y., Kang, J., Kim, D., & Park, C. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s521900 · Cited by 1
Obesity: A Persistent Puzzle-Unveiling Past Missteps and Future Promise in Drug Discovery
Alkhafaji, S. L., & Al-Owaidi, M. F. (2025) · kerbala journal of pharmaceutical sciences · doi:10.62472/kjps.v15.i25.149-174 · Cited by 1
Blümlinger, M., Hamar, F., Werle, M., Föger, F., Hrouda, M., Ludewig, E., Huck, C. W., Heiss, M., & Schwarz, L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114164 · Cited by 1
GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes
Morris, D. (2025) · Independent Nurse · doi:10.12968/indn.2025.10.24 · Cited by 1
Chikamatsu, S., Sakaguchi, K., Michigami, M., Araki, K., Kume, S., Tokuyasu, M., Masuda, T., Fujii, I., Ohtsuki, S., & Ito, S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00902 · Cited by 1
Recombinant live biotherapeutics: A new frontier in peptide drug biosynthesis and precision delivery
Chawla, M., Bhange, O., & Das, B. (2025) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2025.12.002 · Cited by 1
Investigating the SNAC-to-drug ratio for the oral absorption of cyanocobalamin in rats
Chiang, P., Liu, J., Nagapudi, K., Pang, J., Plise, E. G., Dolton, M. J., & Durk, M. R. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104163 · Cited by 1
Cline, L., & Wilson, E. (2026) · Physician Assistant Clinics · doi:10.1016/j.cpha.2025.09.002 · Cited by 1
Fabrication of Peptide Drug Delivery Formulations and Its Characterization Techniques: A Review
Regulagadda, S., Geddam, R., Vasa, T. R. P., Rudhrabatla, V. S. A. P., Thrimurthulu, G., & Padigapati, S. R. (2026) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-025-10798-9 · Cited by 1
Chen, C., Wong, M.-T., Yu, Y., Chu, H., Lim, C., & Chang, T. W. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126752 · Cited by 1
Functionalised mesoporous silica with stearic acid: A novel approach to improve octreotide delivery
Tahan, M. A. A., Russell, C., & Al-Khattawi, A. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126773 · Cited by 1
Chen, Y., Li, J., Delemotte, L., & Mu, Y. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00224 · Cited by 1
Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart
Neumann, J., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040447 · Cited by 1
Pawłowska, I., Kuźbicka, K., Kowalczys, A., Pawłowski, L., & Kocić, I. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1786007 · Cited by 1
Tao, J., Lu, X., Wei, Y., Feng, J., Yang, J., & Qi, J. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c24385 · Cited by 1
Theranostic Study of PSMA-Targeted Radioligands Modified with Enhancer SNAC
Zhang, T., Zhang, Q., He, Z., Wang, Y., Wang, Y., Fang, J., Liu, H., Hong, L., Li, Y. L., Zhang, X., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00613 · Cited by 1
A spatiotemporally controllable magnetic microneedle for targeted gastric drug delivery
Luo, J., Deng, S., Zhang, S., Zhao, Y., Xu, X., An, R., Dai, J., & Ju, Y. (2026) · Biomaterials Science · doi:10.1039/d6bm00271d · Cited by 1
Tiwari, A., Akbar, S., Joseph, A., Malayandi, R., Chilamakuri, S. N., & Natesan, S. (2026) · Xenobiotica · doi:10.1080/00498254.2026.2683901 · Cited by 1
Evidence-informed guidance for the clinical use of oral semaglutide in obesity management
Rubino, D., Wharton, S., Knight, M. G., & Aroda, V. R. (2026) · Postgraduate Medicine · doi:10.1080/00325481.2026.2686467 · Cited by 1
Fredholt, F., Raptis, K., Rønholt, S., Hofmann, M., Varum, F., Blaabjerg, L. I., & Nielsen, H. M. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127237 · Cited by 1
Vignera, S. L., & Condorelli, R. A. (2026) · Pharmaceuticals · doi:10.3390/ph19081236 · Cited by 1
Clinical translation of permeation enhancers
Janjua, T. I., Choi, J.-W., Ross, B. P., Gleeson, J. P., Mitragotri, S., & Popat, A. (2026) · Nature Reviews Materials · doi:10.1038/s41578-026-00954-y · Cited by 1
Peptidomimetics in GPCRs: From structural insights to clinical blockbusters
Li, G., Zhou, Q., & Wang, M. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.09.010 · Cited by 1
Salcaprozate Sodium as a Permeation Enhancer—Mechanism, Applications and Unresolved Questions
Dinkov, B., Koleva, N., & Stavreva, G. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091171 · Cited by 1
Lund, J., Bjelke, J. R., Granata, D., Egebjerg, T., Bardonnet, P.-L., Zhuoran, Z. W., Johansson, E., Poulsen, B. R., Nissen, J. D., Sassene, P. J., et al. (2026) · Blood · doi:10.1182/blood.2026034676 · Cited by 1
Self-citationEvidence-based use of newer agents in type 2 diabetes
Morris, D. (2021) · Journal of Prescribing Practice · doi:10.12968/jprp.2021.3.6.224 · Cited by 1
Advances in the Management of Diabetes and Overweight using Incretin-based Pharmacotherapies
Prajapati, S. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998256797231009062744 · Cited by 1
Oral Delivery of Therapeutic Peptides: Strategies for Product Development
Liu, P. (2023) · Wiley eBooks · doi:10.1002/9781119660699.ch31 · Cited by 1
Neo‐Glycolipid Oximes as Intestinal Permeation Enhancers for Peptide Hormone PYY3‐36
Kalomoiri, P., Mortensen, J. S., Christensen, N. J., Sørensen, K. K., Nielsen, H. M., Jensen, K. J., & Thygesen, M. B. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202401887 · Cited by 1
Advancements and challenges in the management of obesity using pharmacotherapy (Review)
Alotaibi, S. S., Eldrehmy, E. H., Albogami, S. M., Alkhedaide, A. Q., & Dahab, O. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12912 · Cited by 1
Process Development of Protein Therapeutics
Thomas, J. N., Guhan, S., & Pettit, D. K. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc160 · Cited by 1
Delivery of macromolecule therapeutics via jetting in the gastrointestinal tract
Arrick, G. (2020) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 1
Process Development of Protein Therapeutics
Huang, Y., Bowes, B. D., Yang, T., Thomas, J. N., Guhan, S., & Pettit, D. K. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc160.pub2 · Cited by 1
Intestinal Permeation Enhancers Safely Enable the Oral Delivery of Macromolecules
Fein, K. C. (2021) · Figshare · doi:10.1184/r1/13554518 · Cited by 1
GLP-1 Obesity and Diabetes Gerald H Tomkin and Daphne Owens
TOMKIN, G. H. (2019) · Interventions in Obesity & Diabetes · doi:10.31031/iod.2019.03.000553
Building therapy in type 2 diabetes – metformin and beyond
Morris, D. (2021) · Independent Nurse · doi:10.12968/indn.2021.3.14
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Oral Semaglutide for the Treatment of Type 2 Diabetes: A Mini Review
Mikhail, N. (2019) · Series of Endocrinology Diabetes and Metabolism · doi:10.54178/jsedmv1i3002
New Kid on the Block: Semaglutide
Siddhanta, S. (2022) · Bengal Physician Journal · doi:10.5005/jp-journals-10070-7079
Regional Intestinal Drug Absorption
Gonzalez-Alvarez, M. I., & Dahan, A. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-3657-6
Transmucosal Absorption Enhancers in the Drug Delivery Field
Casettari, L., Maher, S., & Illum, L. (2020) · MDPI eBooks · doi:10.3390/books978-3-03921-849-3
2. How to Select Anti-diabetic Drugs
Terauchi, Y. (2021) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.110.556
GLP-1-Rezeptoragonisten und Modulation des kardiovaskulären Risikos
Marx, N. (2022) · CardioVasc · doi:10.1007/s15027-022-3670-1
(2022) · ACS symposium series · doi:10.1021/bk-2022-1417.ix002
(2022) · ACS symposium series · doi:10.1021/bk-2022-1417.ot001
(2022) · ACS symposium series · doi:10.1021/bk-2022-1417.fw001
Optimization of Peptide Drug Exposures for Pharmacological Efficacy: DMPK Considerations
Duggal, R., & Hochman, J. H. (2022) · ACS symposium series · doi:10.1021/bk-2022-1417.ch010
Ghodge, S. V., Biswas, K., & Golosov, A. A. (2022) · ACS symposium series · doi:10.1021/bk-2022-1417.pr001
Orale semaglutide: een nieuwe en eerste orale GLP1-receptoragonist
Soubry, E., Mathieu, C., Vandistel, G., & Mertens, A. C. (2022) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.78.22.068
Current practices in drug delivery for metabolic disorders
Jain, P., Alex, T. S., Singh, M., Hassan, N., Mirza, M. A., & Iqbal, Z. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99616-7.00016-5
Terauchi, Y. (2021) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.110.1872
Cell‐Penetrating Peptides as Tools to Facilitate Oral Delivery of Biopharmaceuticals
Asgreen, C. J., Fredholt, F., Nielsen, H. M., & Kristensen, M. (2022) · Wiley eBooks · doi:10.1002/9783527835997.ch18
Orális peptidbevitel: Innovatív megoldás a diabetológusok kezében
Molnár, G. A. (2022) · Diabetologia Hungarica · doi:10.24121/dh.2022.s1.1
Itin, C., Schwartz, P., Galitzer, H., Toledano, M., & Burshtein, G. (2023) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-023-10532-3
Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
Hong, S. (2023) · BIO Web of Conferences · doi:10.1051/bioconf/20236101006
Du nouveau dans l’administration orale de médicaments: Une capsule aux allures d’œuf de Pâques
Dauvergne, K., Chahine, K., Bellaiche, S., & Deligne, C. (2023) · médecine/sciences · doi:10.1051/medsci/2023107
La oportunidad que supone disponer de un arGLP-1 oral
Orozco‐Beltrán, D. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.manejointegral.art4
Approaching novel antibiotic targets using peptidomimetics
Paulussen, F. M. (2023) · doi:10.5463/thesis.473
Rico-Fontalvo, J. E., Daza-Arnedo, R., Vázquez, L. C., Yánez, T. R., Raad-Sarabia, M., Toapanta, N., Rafael-Vicente, P., Montejo-Hernández, J. D., & Soler, M. J. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.m24000021
Metadata
- Authors
- Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., Pedersen, B. L., Skyggebjerg, R. B., Benie, A. J., Strauss, H. M., Wahlund, P.-O., Bjerregaard, S., Farkas, E., Fekete, C., Søndergaard, F. L., Borregaard, J., Hartoft-Nielsen, M.-L., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk A/S, 2760 Måløv, Denmark.
- HUN-REN Institute of Experimental Medicine (HU)
- Tufts Medical Center (US)
- Novo Nordisk A/S, 2860 Søborg, Denmark.
- Corresponding author
- Buckley, Stephen T.
- Bækdal, Tine A.
- Vegge, Andreas
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-11-14
- Volume
- 10
- Issue
- 467
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2901306081
- Cited by
- 553
- References
- 40
- Citations by year
- 2026: 84 · 2025: 89 · 2024: 74 · 2023: 53 · 2022: 73 · 2021: 77 · 2020: 69 · 2019: 32 · 2018: 1
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, GLP-1 receptor agonists, SNAC, gastric absorption, oral drug delivery, tablet formulation, tight junctions
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Oral, Adolescent, Adult, Aged, Animals, Cell Membrane, Dogs, Glucagon-Like Peptides, Epithelial Cells, Gastric Mucosa, Humans, Hydrogen-Ion Concentration, Intestinal Absorption, Male, Middle Aged, Stomach, Time Factors, Rats, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.